Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer
, y | 19 abr 2016
Acerca de este artículo
Article Category: Review
Publicado en línea: 19 abr 2016
Páginas: 221 - 227
Recibido: 04 feb 2016
Aceptado: 14 feb 2016
DOI: https://doi.org/10.1515/raon-2016-0021
Palabras clave
© 2017 Jasenka Gugic, Lorna Zadravec Zaletel, Irena Oblak
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Risk for coronary artery disease in testicular cancer survivors regarding to different treatment modalities
| Author (year) | N | Period of treatment | Median follow up (range), in years | Age at diagnosis (range) | Age at follow-up (range) | Risk for CAD (CI 95 %) | Treatment Modalities | Note |
|---|---|---|---|---|---|---|---|---|
| Meinardi et al. | 87 | Before 1987 All patients treated with cisplatin based chemotherapy before 1987. | 14 (10 to 20) | 27 (17-36) | 42 (30-50) | SIR=7.1 (1.9 to 18.3) | ChT | Age adjusted results. Older than 50 |
| Huddart et al. | 992 | 1982-1992 | 10.2 (0 to 20.3) | 31.7 (10-82) | 44 (23-78) | RR=1.00 (reference) | Surveillance | Age adjusted results. Only 8.3 % |
| Van der Belt- | 2339 | 1965-1995 | 18.4 (5 to 38.4) | 38.3 Age for seminoma patients. Age for nonseminoma patients. | 59.8 Age for seminoma patients. Age for nonseminoma patients. | SIR=0.94 (0.61 to 1.39) | Surveillance | Patients with CAD before or |
| Haughnes et al. | 990 | 1980-1994 | 19 (13 to 28) | 31 (15-53) | 51 (31-69) | HR=1.0 (reference) | Surveillance | Age adjusted results. Patients with |